WO2022106726A3 - IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES - Google Patents

IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES Download PDF

Info

Publication number
WO2022106726A3
WO2022106726A3 PCT/EP2021/082700 EP2021082700W WO2022106726A3 WO 2022106726 A3 WO2022106726 A3 WO 2022106726A3 EP 2021082700 W EP2021082700 W EP 2021082700W WO 2022106726 A3 WO2022106726 A3 WO 2022106726A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
antigen
treatment
igy
egg
Prior art date
Application number
PCT/EP2021/082700
Other languages
French (fr)
Other versions
WO2022106726A2 (en
Inventor
Lasse EVENSEN
Gorm SANSON
Per Olav Skjervold
Siri HILDONEN
Original Assignee
Norimun As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norimun As filed Critical Norimun As
Publication of WO2022106726A2 publication Critical patent/WO2022106726A2/en
Publication of WO2022106726A3 publication Critical patent/WO2022106726A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The invention relates to antibody compositions, in particular an IgY antibody composition (for example as obtained by immunization of an egg-laying poultry), wherein the compositions comprise antibodies with binding specificity against one or more (such as two, three or four) antigens selected from Angiotensin Converting Enzyme 2 (ACE-2) antigen, Neuropilin 1 (NRP-1) antigen, SARS-CoV-2 Spike 1 Receptor Binding Domain (RBD) antigen, and SARS-CoV-2 Spike Glycoprotein 1 (S1) antigen. The invention further relates to such compositions for use in prevention and/or treatment of an infection of a coronavirus in an animal. The invention further relates to a pharmaceutical composition comprising such a composition. The invention further relates to an egg yolk from an egg from an egg-laying poultry (layer) and/or an IgY composition obtained therefrom, for use in prevention and/or treatment of an infection of a coronavirus in an animal, wherein the egg yolk comprises such IgY antibodies. The invention further relates to a method of in vitro diagnosis, wherein such an IgY antibody composition is contacted with a biological sample from an animal.
PCT/EP2021/082700 2020-11-23 2021-11-23 IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES WO2022106726A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO20201278 2020-11-23
NO20201278 2020-11-23
NO20210841 2021-06-29
NO20210841 2021-06-29

Publications (2)

Publication Number Publication Date
WO2022106726A2 WO2022106726A2 (en) 2022-05-27
WO2022106726A3 true WO2022106726A3 (en) 2022-07-07

Family

ID=78819542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/082700 WO2022106726A2 (en) 2020-11-23 2021-11-23 IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES

Country Status (1)

Country Link
WO (1) WO2022106726A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556113A (en) * 2004-01-07 2004-12-22 珠海百奥生物技术有限公司 Yolk antibody of anti SARS coronavirus and its preparation method and liquid preparation
CN111228483A (en) * 2020-03-19 2020-06-05 四川大学 Broad-spectrum antibody spray for novel coronavirus and SARS virus
CN111808199A (en) * 2020-07-27 2020-10-23 西安咸辅生物科技有限责任公司 Preparation method of ACE2 anti-idiotype yolk antibody vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1556113A (en) * 2004-01-07 2004-12-22 珠海百奥生物技术有限公司 Yolk antibody of anti SARS coronavirus and its preparation method and liquid preparation
CN111228483A (en) * 2020-03-19 2020-06-05 四川大学 Broad-spectrum antibody spray for novel coronavirus and SARS virus
CN111808199A (en) * 2020-07-27 2020-10-23 西安咸辅生物科技有限责任公司 Preparation method of ACE2 anti-idiotype yolk antibody vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSEN BRIAN: "IgY antibodies-sustainable and efficacious therapeutics for human and animal health", BIOPHARMADEALMAKERS.NATURE.COM, 1 September 2020 (2020-09-01), XP055897238, Retrieved from the Internet <URL:http://citenpl.internal.epo.org/wf/web/citenpl/citenpl.html?_url=https%3A%2F%2Fmedia.nature.com%2Foriginal%2Fmagazine-assets%2Fd43747-020-01049-5%2Fd43747-020-01049-5.pdf> [retrieved on 20220303] *
LU YAN ET AL: "Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2020, 16 October 2020 (2020-10-16), US, pages 1 - 8, XP055872677, ISSN: 2314-8861, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/jir/2020/9465398.xml> DOI: 10.1155/2020/9465398 *

Also Published As

Publication number Publication date
WO2022106726A2 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
WO2021156490A3 (en) Corona virus binders
US20210269512A1 (en) Antibodies against disease causing agents of poultry and uses thereof
TWI445547B (en) Dengue virus peptide vaccine and methods of preparing and using the same
CN103687619A (en) Compositions and methods for the therapy and diagnosis of influenza
CN104640878A (en) Cross-reactive staphylococcus aureus antibody
Cecchini et al. Evaluation of the effects of dexamethasone-induced stress on levels of natural antibodies in immunized laying hens
Karachaliou et al. IgY technology: Methods for developing and evaluating avian immunoglobulins for the in vitro detection of biomolecules
WO2020099922A1 (en) Antibodies against disease causing agents of canines and felines and uses thereof
US20170196971A1 (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
CN103665155A (en) Anti-influenza-virus broad-spectrum-neutrality neutralizing molecule 1F2
van Ginkel et al. Induction of mucosal immunity in the avian Harderian gland with a replication-deficient Ad5 vector expressing avian influenza H5 hemagglutinin
El-Kafrawy et al. Immunotherapeutic efficacy of IgY antibodies targeting the full-length spike protein in an animal model of middle east respiratory syndrome coronavirus infection
Carmena et al. Characterization of excretory–secretory products from protoscoleces of Echinococcus granulosus and evaluation of their potential for immunodiagnosis of human cystic echinococcosis
Benčina et al. Transfer of maternal immunoglobulins and antibodies to Mycoplasma gallisepticum and Mycoplasma synoviae to the allantoic and amniotic fluid of chicken embryos
ATE353337T1 (en) ADHESIN FROM HELIOBACTER PYLORI, WHICH BINDS TO BLOOD GROUP ANTIGENS
WO2022106726A3 (en) IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES
CA2747696A1 (en) Method for preparing comprehensive anti-surface antibody using microorganism immobilized as antigen with protein crosslinking and immobilization reagent
US20070231320A1 (en) Eggs having increased antibody titer and methods for making same
Huang et al. Different neutralization efficiency of neutralizing monoclonal antibodies against avian influenza H5N1 virus to virus strains from different hosts
WO2022200291A3 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
JP2021516340A (en) Species-specific antigen sequence and usage for tick-borne relapsing fever (TBRF)
WO2012173244A1 (en) Marker for use in detection of periodontopathic bacterium communicable between men and animals
JP2015536145A (en) Enrichment of antigen-specific plasmablasts
Zhang et al. Production, purification and characterization of polyclonal antibody against the truncated gK of the duck enteritis virus
CN103665153A (en) Anti-influenza-virus broad-spectrum-neutrality neutralizing molecule 1E1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21816057

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21816057

Country of ref document: EP

Kind code of ref document: A2